Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors

Conclusions EGFR exon 20 insertional mutations, including three that were previously unreported, were associated with the poor response of patients to TKI treatment.

http://link.springer.com/10.1007/s10637-014-0146-x

Source: Investigational New Drugs - November 11, 2014 Category: Drugs & Pharmacology Source Type: research